Contacts
Destra Capital Advisors LLC
DMA@destracapital.com
(877) 855-3434
Destra Multi-Alternative Fund (the “Fund” or DMA”) announced today that the Fund’s Board of Trustees approved an Amended and Restated Declaration of Trust with the addition of a Forum Selection Clause as well as the filing of an 8-K.
For more information regarding the Fund, Destra Capital Advisors, and the Amended and Restated Declaration of Trust, visit the Fund webpage below:
http://www.destracapital.com/strategies/closed-end-funds/destra-multi-alternative-fund
About Destra Multi Alternative Fund:
Destra Multi-Alternative Fund (NYSE:DMA) is a core alternative solution that seeks to achieve long-term performance non-correlated to the broad stock and bond markets.
Destra Capital Advisors LLC, based in Bozeman, MT, serves as Investment Adviser and Secondary Market Servicing agent to the Fund. Validus Growth Investors serves as the Investment Sub-Adviser to the Fund.
Shares of the Fund can be purchased on the New York Stock Exchange through any securities broker.
Please contact Destra Capital Advisors LLC, the Fund’s marketing, and investor support services agent, at DMA@destracapital.com or call (877) 855-3434 if you have any questions regarding DMA.
NOT FDIC INSURED |
NO BANK GUARANTEE |
MAY LOSE VALUE |
View source version on businesswire.com: https://www.businesswire.com/news/home/20231117219560/en/
Related news for (DMA)
- ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
- ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
- ADMA Biologics Statement on Tariffs
- ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke